Home  /  Engagements

Different use cases, one question.

Where does the value leave?

Representative use cases drawn from actual projects, organized by where the product sat in its commercial life when the question was asked. They are indicative, not an exhaustive list of the practice’s work. Client names, brand names and identifying details are withheld. No performance figures appear.

Follow three things, in this order

FirstFollow the patientWhere can the patient fail to reach, start or remain on therapy?
ThenFollow the transactionWhat access, pharmacy, channel, payer and affordability events actually occur?
ThenFollow the financial outcomeWhere does each event land in Gross-to-Net, net revenue and profitability?

The sequence is not interchangeable. Each question is only answerable once the one before it has been answered.

Phase 1Pre-Launch and Launch Readiness
Patient-based forecasting, scenario modeling, launch readiness

Ultra-Rare Pre-Launch Patient Demand Modeling and Launch Readiness

How many patients can realistically be identified, initiated and retained?

Read the use case

Situation

A therapy for an ultra-rare neurological disorder was approaching launch. The observable population was extremely small and claims data were thin, so a traditional epidemiology forecast was not enough. Leadership needed to know what commercial conditions had to be true for the forecast to hold.

What we did

  • Built a patient-based forecast around the full conversion path: opportunity, diagnosis, addressable population, new starts, access, fulfillment, persistence and total volume.
  • Evaluated eighteen potential outcomes using therapeutic analogs, reviewed with external clinical and analytics input, and ran Monte Carlo simulation to produce a range instead of a single point.
  • Modeled persistence independently, with low, base and high cases drawn from the simulated distribution.

What it produced

  • A probabilistic forecast that named which assumptions had to hold for the central case.
  • Quality of Access treated as a core forecast variable, not a downstream launch activity.
  • A resource allocation tool that tested both directions of risk: under-investment and over-investment.

An ultra-rare forecast is not an epidemiology model. It is a commercialization conversion model. Written, approved, filled and persistent demand are four different numbers.

Related services

Financial Planning and Demand Forecasting →

Commercialization strategy, scenario design, launch investment planning

505(b)(2) Pre-Launch Commercialization Strategy

What combination of access, channel, price and investment creates the most defensible path to profitability?

Read the use case

Situation

A differentiated 505(b)(2) product was entering a category that was still forming. The manufacturer had to balance patient adoption, competitive positioning, payer access, channel design, investment, Gross-to-Net and long-term profitability at the same time.

What we did

  • Developed an independent commercialization thesis rather than validating the base case.
  • Ran the full chain from clinical and regulatory assumptions through market formation, demand, adoption, access, channel, pricing and Gross-to-Net to net sales and profitability.
  • Rebuilt the market around the forming category, and tested list price and rebate trade-offs, retail, specialty, cash and direct distribution, field models and contracting strategy.

What it produced

  • A scenario framework spanning base, conservative, higher-investment and alternative go-to-market constructs, including high list with rebates and lower list with direct distribution.
  • One decision framework holding Finance, Market Access, Commercial, Patient Services, Trade and Forecasting in a single view.

Individually reasonable functional assumptions can assemble into materially different enterprise outcomes. A launch forecast is only as credible as the commercialization system built to deliver it.

Related services

Payer and Formulary Strategy →Financial Planning and Demand Forecasting →

Phase 2Launch and Early Commercialization
Access technology validation, workflow assessment, executive measurement narrative

Prior Authorization Intelligence and Patient Hub Workflow Assessment

What does the capability actually do, and how should it expand?

Read the use case

Situation

A prior authorization intelligence capability was in pilot inside an existing patient hub workflow. Leadership needed a defensible view of what it did, how it performed, and how to sequence expansion without overstating its value.

What we did

  • Traced the prescription from creation through coverage determination and fulfillment, mapping where the capability intervened and what decision it informed.
  • Held the claim to what was true: it evaluates whether a prescription aligns with payer policy. It does not predict whether a payer will approve.
  • Corrected earlier assumptions about which pharmacy pathways were live, so the baseline reflected reality rather than planned architecture.

What it produced

  • An executive workflow assessment with a measurement narrative that would survive scrutiny.
  • A corrected operational baseline.
  • A sequenced expansion path separating connected-practice environments from broader extension.

Access technology fails on credibility before it fails on capability. Precision about what a capability does is a prerequisite to sustaining investment in it.

Related services

Prior Authorization and Access Enablement →

Phase 3In-Market Optimization
Channel architecture, affordability governance, patient journey orchestration

Patient Access, Channel and Affordability Redesign

Where can a prescription disappear, and can the manufacturer see why?

Read the use case

Situation

A high-demand brand had strong prescriber demand and was losing opportunity between prescription creation and therapy initiation. It needed more appropriate patients converting, better visibility, controlled affordability spend and protected economics.

What we did

  • Followed the prescription through coverage, prior authorization, affordability, pharmacy, fulfillment, patient, data and economics.
  • Found a fragmented channel where the same prescription met different journeys depending on the pharmacy, a non-mandatory patient hub, and prior authorization handled mostly by hand.
  • Declined to assume a patient hub, specialty pharmacy, copay program or field intervention was the answer before the diagnosis was complete.

What it produced

  • A future-state architecture orchestrated across technologies and partners rather than delegated to a single vendor.
  • A governance principle: see leakage and patient behavior first, then let that decide the adjudication model.
  • A controlled migration rather than a disruptive replacement.

Do not change the affordability mechanism before you can see what is actually happening. Demand is not access, and access is not fulfillment.

Related services

Affordability and Copay Governance →Patient Journey Optimization →

Channel optionality, patient orchestration, copay adjudication governance

Specialty Channel, Patient Orchestration and Affordability Governance

Can the manufacturer see where every patient is, and who owns the next step?

Read the use case

Situation

A rare disease product where every patient carries outsized clinical and economic weight. The manufacturer needed better conversion, less dependence on a concentrated channel, stronger affordability controls, and visibility into patient and financial outcomes.

What we did

  • Followed the patient across the whole pathway rather than evaluating the patient hub, specialty pharmacy, copay program and payers separately.
  • Found heavy concentration in one specialty pharmacy tied to a vertically integrated payer and PBM ecosystem, with benefits verification sitting inside the same organization.
  • Mapped a non-mandatory patient hub, manual prior authorization, and exposure to accumulators and maximizers.

What it produced

  • Patient hub orchestration as an enabling layer that sees the patient before downstream channel complexity.
  • An independent specialty pharmacy evaluated for optionality, benchmarking and data transparency.
  • Independent copay adjudication and a uniform data architecture giving one patient-level view, whoever dispensed.

The organization that dispenses the medicine does not need to control the patient journey. Copay is not a patient-service expense. It is a commercialization transaction that requires financial governance.

Related services

Patient Journey Optimization →Affordability and Copay Governance →

Revenue leakage diagnostics, Gross-to-Net analysis, channel economics

In-Market Revenue Leakage Diagnostic

Where between prescription and net revenue is the value being lost?

Read the use case

Situation

A commercialized brand was generating prescription volume that was not translating into expected return. Leadership could see the variance on the income statement and could not see where it came from.

What we did

  • Worked backward through prescription, access, pharmacy, affordability, fulfillment, utilization, Gross-to-Net, net revenue and profitability.
  • Examined payer and rebate economics, distribution, copay leakage, pharmacy performance, fulfillment, utilization and field deployment.
  • Found that two territories with similar prescription activity produced materially different economics, depending on payer mix, pharmacy behavior, copay utilization and net price.

What it produced

  • Copay audit and recovery, to find where copay dollars were and were not producing incremental access.
  • Pharmacy segmentation by ability to convert prescriptions into filled, persistent patients.
  • Contracting optimization testing whether rebated access was paying for itself, and field targeting informed by patient economics.

Revenue leakage does not begin on the income statement. It begins somewhere in the patient journey. The financial outcome is simply where it finally becomes visible.

Related services

Revenue Leakage Diagnostics →GPO Contract Management and Validation →

Phase 4Lifecycle and Loss of Exclusivity
Lifecycle strategy, authorized generic economics, channel redesign

Lifecycle Profitability, Channel Redesign and Loss-of-Exclusivity Strategy

Can the market be transitioned on purpose before exclusivity loss?

Read the use case

Situation

An established pediatric brand needed better profitability and patient-access performance while preparing for generic pressure and eventual loss of exclusivity.

What we did

  • Assessed payer behavior, access restrictions, patient economics, reimbursement, channel, current Gross-to-Net and authorized-generic economics, including doing nothing versus intervening early.
  • Established that aggregate Gross-to-Net was not enough. Payer-specific net price was required, with government pricing effects including Medicaid CPI penalties and AMP.
  • Made prescription-to-fill confidence the central objective, because a prescription written is not a patient started.

What it produced

  • An alternative channel architecture to shorten time to fill, improve prior authorization and appeals, show failed prescriptions and make pharmacy networks consistent.
  • A lifecycle plan through the authorized generic and the move to a multi-source market.
  • A reframed question: not what price to set, but whether to transition the market before generics arrive.

Loss of exclusivity is not a pricing event. It is a commercialization transition.

Related services

Channel Architecture and Net Price Optimization →Accrual Design and True-Up Governance →

From strategy to execution

We start with the strategy you already have.

We do not begin by replacing the strategy your team, or another advisor, has already built. We begin by connecting it to the market it is about to meet.

  1. 01Strategy
  2. 02Evidence and assumptions
  3. 03Commercialization alignment
  4. 04Patient and financial pressure test
  5. 05Execution roadmap
  6. 06Measurement